Abstract:Background and Aims This study investigated the feasibility, safety, and efficacy of transarterial chemoembolization (TACE) combined with CT-guided 125 iodine seed implantation for treatment of hepatocellular carcinoma (HCC) with first-branch portal vein tumor thrombosis (PVTT). Methods This prospective, controlled, multicenter study included HCC patients with Barcelona Clinic Liver Cancer stage C disease and PVTT in the right and/or left portal veins. Patients were treated with either TACE and sorafenib or TACE and CT-guided 125 iodine seed implantation and regularly evaluated for clinical response and adverse events, with treatment termination resulting from declining clinical status, loss to follow-up, or death. Results This study demonstrated a significant between-group difference in median overall survival (OS); therefore, it was terminated early. A total of 123 patients were included in this study, with 52 patients in the TACE-sorafenib group and 71 patients in the TACE- 125 iodine group, without significant differences in baseline characteristics between groups. The median OS was 8.3 months (95% CI: 6.105–10.495) in the TACE-sorafenib group and 13.8 months (95% CI: 9.519–18.081) in the TACE- 125 iodine group. In a subgroup analysis of type IIa versus type IIb PVTT, the median OS was 17.5 months for type IIa and 7.1 months for IIb in the TACE- 125 iodine group. The median OS was 9.3 months for IIa and 4.0 months for IIb in the TACE-sorafenib group. Univariate and multivariate analyses confirmed that the PVTT type and treatment strategy were significant independent factors affecting OS. The objective response rates (ORR) for intrahepatic lesions and PVTT showed significant differences between groups. Most patients in both groups experienced minor adverse events related to TACE. The overall incidence of sorafenib-related adverse events or toxic effects was 90.4% in TACE-sorafenib group. In the TACE- 125 iodine group, the incidence of pneumothorax and minor hepatic subcapsular hemorrhage were 7.04% and 9.86%, respectively. Conclusions This study showed that TACE- 125 iodine treatment significantly enhanced survival of patients with HCC and type II PVTT, especially subtype IIa, with minimal adverse events. Clinical Trial Registration Chinese Clinical Trials Database, identifier ChiCTR-ONN-16007929.

Preliminary Results of Main Portal Vein Tumor Thrombus Treated by Endovascular Brachytherapy Combined with Sorafenib

Combined Endovascular Brachytherapy, Sorafenib, and Transarterial Chemobolization Therapy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.

Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus

Endovascular Brachytherapy Combined with Portal Vein Stenting and Transarterial Chemoembolization Improves Overall Survival of Hepatocellular Carcinoma Patients with Main Portal Vein Tumor Thrombus.

Irradiation stent with <SUP>125</SUP>I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial

HCC with Main Portal Vein Tumor Thrombus Treated by Stent Placement and TACE Combined with Endovascular Brachytherapy or Three Dimensional Conformal Radiotherapy

Endovascular brachytherapy vs.sequential three-dimensional conformal radiotherapy for the treatment of main portal vein tumor thrombus: a comparative study

Treatment of Hepatocellular Carcinoma-associated Portal Vein Tumor Thrombus Using Combination of Portal Vein Stent Insertion and Endovascular Lodine-125 Seed-strip Implantation Followed by Transcatheter Arterial Chemoembolization- Sorafenib

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

[Endovascular placement of iodine-125 seed strand and self-expandable stent combined with transcatheter arterial chemoembolization for hepatocellular carcinoma with tumor thrombus in the main portal vein].

A combination of portal vein stent insertion and endovascular iodine-125 seed-strip implantation, followed by transcatheter arterial chemoembolization with sorafenib for treatment of hepatocellular carcinoma-associated portal vein tumor thrombus

Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis

Portal Vein Stenting Combined 125I Particle Implanted Followed by Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs.125Iodine Implantation

Transarterial Chemoembolization Combined with Sorafenib for the Treatment of Hepatocellular Carcinoma with Hepatic Vein Tumor Thrombus

Efficacy and Safety of Endovascular Brachytherapy Combined with Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma Patients with Type III or IV Portal Vein Tumor Thrombosis

Randomized comparative study of HCC with MPVTT treated by portal vein stent and TACE combined with or without

Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine-125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus]

Sorafenib with and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Retrospective Analysis

Endovascular brachytherapy with iodine-125 seed strand for extensive portal vein tumor thrombus in patients with hepatocellular carcinoma

Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein.